MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-20T21:00:00Z
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Mon 21 Oct 24, 01:50 PMWith 88% ownership, McKesson Corporation (NYSE:MCK) boasts of strong institutional backing
Fri 18 Oct 24, 01:00 PMMcKesson (MCK) Rises As Market Takes a Dip: Key Facts
Tue 15 Oct 24, 10:00 PMHere’s How The Post-COVID Market Normalization Affected McKesson Corporation (MCK)
Fri 11 Oct 24, 02:14 PMIs Trending Stock McKesson Corporation (MCK) a Buy Now?
Thu 10 Oct 24, 01:00 PMMcKesson (MCK) Outpaces Stock Market Gains: What You Should Know
Wed 09 Oct 24, 10:00 PMMcKesson Corporation (MCK): One of the Best Stocks to Buy According to Larry Robbins
Mon 07 Oct 24, 05:40 AMJim Cramer on McKesson Corporation (MCK): ‘It’s Time To Buy It’
Fri 04 Oct 24, 08:52 PMMcKesson (MCK) Stock Dips While Market Gains: Key Facts
Wed 02 Oct 24, 10:00 PM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 4630.00M | 1928.00M | -5034.00000M | 1144.00M | 610.00M |
| Minority interest | 162.00M | -173.00000M | 199.00M | 220.00M | 221.00M |
| Net income | 3560.00M | 1114.00M | -4339.00000M | 900.00M | 34.00M |
| Selling general administrative | 15552.00M | 21074.00M | 17698.00M | 18336.00M | 8403.00M |
| Selling and marketing expenses | -7776.00000M | -10537.00000M | -8849.00000M | -9168.00000M | 8403.00M |
| Gross profit | 12358.00M | 13130.00M | 12148.00M | 12023.00M | 11754.00M |
| Reconciled depreciation | 608.00M | 760.00M | 887.00M | 922.00M | 949.00M |
| Ebit | 4381.00M | 2852.00M | 3522.00M | 1663.00M | 3268.00M |
| Ebitda | 5687.00M | 3612.00M | 4409.00M | 2585.00M | 4217.00M |
| Depreciation and amortization | 1306.00M | 760.00M | 887.00M | 922.00M | 949.00M |
| Non operating income net other | 497.00M | 68.00M | 223.00M | 12.00M | -12.00000M |
| Operating income | 4381.00M | 2852.00M | 3522.00M | 1663.00M | 886.00M |
| Other operating expenses | 272129.00M | 261373.00M | 234929.00M | 228292.00M | 211039.00M |
| Interest expense | 248.00M | 178.00M | 217.00M | 249.00M | 264.00M |
| Tax provision | 905.00M | 636.00M | -695.00000M | 18.00M | 356.00M |
| Interest income | 248.00M | 10.00M | 217.00M | 49.00M | 39.00M |
| Net interest income | -248.00000M | -178.00000M | -217.00000M | -200.00000M | -225.00000M |
| Extraordinary items | -3.00000M | -5.00000M | -1.00000M | -6.00000M | 87.00M |
| Non recurring | -8.00000M | 274.00M | 8339.00M | 270.00M | 2394.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 905.00M | 636.00M | -695.00000M | 18.00M | 356.00M |
| Total revenue | 276711.00M | 263966.00M | 238228.00M | 231051.00M | 214319.00M |
| Total operating expenses | 7776.00M | 10537.00M | 8849.00M | 9264.00M | 8474.00M |
| Cost of revenue | 264353.00M | 250836.00M | 226080.00M | 219028.00M | 202565.00M |
| Total other income expense net | 249.00M | -924.00000M | -8556.00000M | -519.00000M | -2406.00000M |
| Discontinued operations | -3.00000M | -5.00000M | -1.00000M | -6.00000M | 1.00M |
| Net income from continuing ops | 3725.00M | 1292.00M | -4339.00000M | 1126.00M | 254.00M |
| Net income applicable to common shares | 3560.00M | 1114.00M | -4539.00000M | 900.00M | 34.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 62320.00M | 63298.00M | 65015.00M | 61247.00M | 59672.00M |
| Intangible assets | 2277.00M | 2059.00M | 2878.00M | 3156.00M | 3689.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 496.00M | 5414.00M | 665.00M | 617.00M | 529.00M |
| Total liab | 63810.00M | 65090.00M | 63569.00M | 54536.00M | 49992.00M |
| Total stockholder equity | -1857.00000M | -2272.00000M | -21.00000M | 5092.00M | 8094.00M |
| Deferred long term liab | 1387.00M | 1418.00M | 1411.00M | 2255.00M | 2998.00M |
| Other current liab | 4200.00M | 9284.00M | 9.00M | 683.00M | 3443.00M |
| Common stock | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
| Capital stock | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
| Retained earnings | 12295.00M | 9030.00M | 8202.00M | 13022.00M | 12409.00M |
| Other liab | 9808.00M | 10142.00M | 11193.00M | 3917.00M | 5068.00M |
| Good will | 9947.00M | 9451.00M | 9493.00M | 9360.00M | 9358.00M |
| Other assets | 1755.00M | 1251.00M | 2581.00M | 1858.00M | 1705.00M |
| Cash | 4678.00M | 3532.00M | 6278.00M | 4015.00M | 2981.00M |
| Cash and equivalents | 4678.00M | 3532.00M | 6278.00M | 4015.00M | 2981.00M |
| Total current liabilities | 47957.00M | 48466.00M | 44103.00M | 42624.00M | 37626.00M |
| Current deferred revenue | - | - | 3987.00M | 3340.00M | - |
| Net debt | 2617.00M | 4010.00M | 3127.00M | 5386.00M | 4614.00M |
| Short term debt | 1267.00M | 1096.00M | 1132.00M | 1406.00M | 330.00M |
| Short long term debt | 968.00M | 799.00M | 742.00M | 1052.00M | 330.00M |
| Short long term debt total | 7295.00M | 7542.00M | 9405.00M | 9401.00M | 7595.00M |
| Other stockholder equity | -13250.00000M | -9770.00000M | -6745.00000M | -6229.00000M | -2469.00000M |
| Property plant equipment | 2177.00M | 2092.00M | 2581.00M | 2365.00M | 2548.00M |
| Total current assets | 44292.00M | 46231.00M | 45382.00M | 42222.00M | 38465.00M |
| Long term investments | - | - | - | 0.00000M | 3513.00M |
| Net tangible assets | -12679.00000M | -12416.00000M | -9254.00000M | -4362.00000M | -3560.00000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 19410.00M | 18583.00M | 19181.00M | 19950.00M | 18246.00M |
| Long term debt | 4626.00M | 5080.00M | 6406.00M | 6335.00M | 7265.00M |
| Inventory | 19691.00M | 18702.00M | 19246.00M | 16734.00M | 16709.00M |
| Accounts payable | 42490.00M | 38086.00M | 38975.00M | 37195.00M | 33853.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 367.00M | 480.00M | 196.00M | 217.00M | 193.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -905.00000M | -1534.00000M | -1480.00000M | -1703.00000M | -1849.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 12295.00M | 9030.00M | 8202.00M | 13022.00M | 12409.00M |
| Treasury stock | - | -17045.00000M | -13670.00000M | -12892.00000M | -8902.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1992.00M | 1917.00M | 2581.00M | 2258.00M | 2099.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 18028.00M | 17067.00M | 19633.00M | 19025.00M | 21207.00M |
| Capital lease obligations | 1701.00M | 1663.00M | 2257.00M | 2014.00M | - |
| Long term debt total | 4626.00M | 5080.00M | 6406.00M | 6335.00M | 7265.00M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -542.00000M | -89.00000M | 400.00M | 37.00M | -1381.00000M |
| Change to liabilities | 4151.00M | 3045.00M | 1101.00M | 3944.00M | 1881.00M |
| Total cashflows from investing activities | -542.00000M | -89.00000M | -415.00000M | -579.00000M | -1381.00000M |
| Net borrowings | -277.00000M | -1334.00000M | -540.00000M | -298.00000M | -16.00000M |
| Total cash from financing activities | -4368.00000M | -6321.00000M | -1693.00000M | -2734.00000M | -2227.00000M |
| Change to operating activities | -1370.00000M | 49.00M | 8216.00M | -377.00000M | -377.00000M |
| Net income | 3722.00M | 1287.00M | -4340.00000M | 1120.00M | 255.00M |
| Change in cash | 743.00M | -2461.00000M | 2373.00M | 1042.00M | 309.00M |
| Begin period cash flow | 3935.00M | 6396.00M | 4023.00M | 2981.00M | 2672.00M |
| End period cash flow | 4678.00M | 3935.00M | 6396.00M | 4023.00M | 2981.00M |
| Total cash from operating activities | 5159.00M | 4434.00M | 4542.00M | 4374.00M | 4036.00M |
| Issuance of capital stock | 163.00M | 220.00M | 92.00M | 113.00M | 75.00M |
| Depreciation | 608.00M | 760.00M | 887.00M | 922.00M | 949.00M |
| Other cashflows from investing activities | -152.00000M | 299.00M | -364.00000M | -254.00000M | -955.00000M |
| Dividends paid | -292.00000M | -277.00000M | -276.00000M | -294.00000M | 292.00M |
| Change to inventory | -1259.00000M | -1169.00000M | -2276.00000M | -376.00000M | -368.00000M |
| Change to account receivables | -1082.00000M | -1843.00000M | 1145.00M | -2494.00000M | -967.00000M |
| Sale purchase of stock | -3638.00000M | -3516.00000M | -770.00000M | -1954.00000M | -1639.00000M |
| Other cashflows from financing activities | 9123.00M | 10092.00M | 6624.00M | 21136.00M | 38009.00M |
| Change to netincome | 140.00M | 2064.00M | -525.00000M | 193.00M | 2304.00M |
| Capital expenditures | 558.00M | 535.00M | 641.00M | 506.00M | 557.00M |
| Change receivables | -1082.00000M | -1843.00000M | 1145.00M | -2494.00000M | -967.00000M |
| Cash flows other operating | -1121.00000M | 290.00M | 8550.00M | 1065.00M | 68.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 249.00M | -1976.00000M | 2434.00M | 1061.00M | 428.00M |
| Change in working capital | 384.00M | 82.00M | 8186.00M | 689.00M | 546.00M |
| Stock based compensation | - | - | 233.00M | 1223.00M | 2273.00M |
| Other non cash items | 465.00M | 2271.00M | 484.00M | 762.00M | -176.00000M |
| Free cash flow | 4601.00M | 3899.00M | 3901.00M | 3868.00M | 3479.00M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation |
5.49 0.89% | 621.14 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
| COR Cencora Inc. |
2.17 0.90% | 243.15 | 23.39 | - | - | - | ||
| CAH Cardinal Health Inc |
2.01 1.70% | 120.34 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
| HSIC Henry Schein Inc |
-1.06 1.42% | 73.78 | 24.12 | 14.04 | 0.74 | 2.50 | 0.95 | 13.33 |
| SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
0.52 45.61% | 1.66 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
6555 State Highway 161, Irving, TX, United States, 75039
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Director | 1967 |
| Mr. Britt J. Vitalone | Exec. VP & CFO | 1969 |
| Ms. Nancy Avila | Exec. VP, Chief Information Officer & CTO | 1967 |
| Ms. Lori A. Schechter J.D. | Exec. VP, Chief Legal Officer & Gen. Counsel | 1962 |
| Mr. Napoleon B. Rutledge Jr. | Sr. VP, Controller & Chief Accounting Officer | 1972 |
| Ms. Holly Weiss | Sr. VP of Investor Relations | NA |
| Mr. Pete Slone | Sr. VP of Corp. Public Affairs | NA |
| Ms. LeAnn B. Smith | Exec. VP & Chief HR Officer | NA |
| Mr. Kirk Kaminsky | Pres of The US Pharmaceutical & Specialty Solutions Bus. | NA |
| Paul A. Smith | Sr. VP of Taxes | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...